×
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
https://ascopost.com/issues/july-10-2021/adapt-trial-excellent-outcomes-reported-with-neoadjuvant-dual-her2-therapy-in-breast-cancer/

Jul 10th, 2021 - The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of pertuzumab/trastuzumab alone—can yield benefits in survival outcomes.1 “For the first time, we have shown both ex...

ASCO Congratulates Chiquita Brooks-LaSure on Confirmation as CMS Administrator
https://ascopost.com/issues/july-10-2021/asco-congratulates-chiquita-brooks-lasure-on-confirmation-as-cms-administrator/

Jul 10th, 2021 - Monica M. Bertagnolli, MD, FACS, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), issued the following statement. Monica M. Bertagnolli, MD, FACS, FASCO Chiquita Brooks-LaSure “The Association for Clinical Oncology congratulates Chiquita Brooks-LaSure on her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Brooks-LaSure is now...

Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC
https://ascopost.com/issues/july-10-2021/amivantamablazertinib-combination-may-overcome-osimertinib-resistance-in-patients-with-egfr-positive-nsclc/

Jul 10th, 2021 - Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the CHRYSALIS trial presented at the 2021 ASCO Annual Meeting.1 The study also provided insights into...

A Shift in the Treatment of Advanced Melanoma
https://ascopost.com/issues/july-10-2021/a-shift-in-the-treatment-of-advanced-melanoma/

Jul 10th, 2021 - Answers to questions about first-line treatment of metastatic melanoma are “going to be shifting,” Jason J. Luke, MD, told The ASCO Post, with the change coming on the heels of the phase III RELATIVITY-047 trial reported at the 2021 ASCO Annual Meeting.1 That abstract reported that using two immunotherapy agents blocking different checkpoints—nivolumab blocking PD-1 and relatlimab blocking LAG-...

ASCO Releases New Recommendations on Systemic Therapy Dosing for Adults With Obesity and Cancer
https://ascopost.com/issues/july-10-2021/asco-releases-new-recommendations-on-systemic-therapy-dosing-for-adults-with-obesity-and-cancer/

Jul 10th, 2021 - ASCO has approved new recommendations for the appropriate dosing of systemic anticancer agents in adults with obesity and cancer.1 The guideline update was based on evidence collected from a systematic review of the literature published between November 1, 2010, and March 27, 2020, regarding dosing of chemotherapy, immunotherapy, and targeted therapies in obese adults with cancer. The original ...

ASCO Releases Rapid Guideline Recommendation Update for Patients With High-Risk, HER2-Negative, Germline BRCA–Mutated Breast Cancer
https://ascopost.com/issues/july-10-2021/asco-releases-rapid-guideline-recommendation-update-for-patients-with-high-risk-her2-negative-germline-brca-mutated-breast-cancer/

Jul 10th, 2021 - A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk, early-stage, HER2-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020 guideline from ASCO, the American Society for Radiation Oncology (ASTRO), and the Society of Surgic...

Being Both a Cancer Provider and a Cancer Survivor Is a Rare Privilege
https://ascopost.com/issues/july-10-2021/being-both-a-cancer-provider-and-a-cancer-survivor-is-a-rare-privilege/

Jul 10th, 2021 - If there is a silver lining in the cloud, it is in a newfound opportunity to bring a personal experience–based authenticity to the clinic. Perhaps my 35-year career as a surgical oncologist and researcher specializing in soft-tissue sarcomas should have prepared me to recognize the signs of chronic lymphocytic leukemia (CLL) when they first appeared a few days before Christmas in 2016, but it d...

Breast Cancer Expert Joseph A. Sparano, MD, FACP, to Join Mount Sinai Health System
https://ascopost.com/issues/july-10-2021/breast-cancer-expert-joseph-sparano-to-join-mount-sinai-health-system/

Jul 10th, 2021 - Mount Sinai Health System has recruited an internationally recognized expert in the management of breast cancer and human immunodeficiency virus (HIV)-associated malignancies, Joseph A. Sparano, MD, FACP, as Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute (TCI). Dr. Sparano will also hold the Ezra M. Greenspan, MD Professorship in Clinical Cancer Thera...

Caryn Lerman, PhD, Elected President of the AACI
https://ascopost.com/issues/july-10-2021/caryn-lerman-phd-elected-president-of-the-aaci/

Jul 10th, 2021 - Caryn Lerman, PhD Karen E. Knudsen, MBA, PhD Caryn Lerman, PhD, is the new President of the Association of American Cancer Institutes (AACI). Dr. Lerman is Director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles and Associate Dean for Cancer Programs and the H. Leslie and Elaine S. Hoffman Professor in Cancer Research at Keck School of Medicine ...

Disease Risk Associated With Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes
https://ascopost.com/issues/july-10-2021/disease-risk-associated-with-protein-truncating-and-rare-missense-variants-in-breast-cancer-risk-genes/

Jul 10th, 2021 - Leila Dorling, PhD In a study reported in TheNew England Journal of Medicine, Leila Dorling, PhD, of the Centre for Cancer Genetic Epidemiology, Departments of Public Health and Primary Care, University of Cambridge, United Kingdom, and colleagues in the international Breast Cancer Association Consortium (BCAC), identified the risk of breast cancer associated with germline protein–truncating an...

Conquer Cancer, the ASCO Foundation, Awards More Than $10 Million to Support Cancer Research
https://ascopost.com/issues/july-10-2021/conquer-cancer-the-asco-foundation-awards-more-than-10-million-to-support-cancer-research/

Jul 10th, 2021 - Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its awards supporting researchers with projects spanning across many areas in cancer care, including immunotherapy, precision medicine, breast cancer, and palliative care. This year, Conquer Cancer is funding the largest number of Young Investigator Awards (YIAs) ever and the most Career Development Awards (CDAs) in t...

Early Adopter of Breast Conservation, Surgical Oncologist Augusto Leon, MD, Reflects on Cancer Care in Chile
https://ascopost.com/issues/july-10-2021/early-adopter-of-breast-conservation-surgical-oncologist-augusto-leon-md-reflects-on-cancer-care-in-chile/

Jul 10th, 2021 - In this installment of the occasional department on Global Health-Care Equity, Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Augusto Leon, MD, a surgical oncologist and Head of the Program of Cancer at Pontifical University of Chile, Santiago. Dr. Are is JL & CJ Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha. “We can...

Defining Cure in Multiple Myeloma
https://ascopost.com/issues/july-10-2021/defining-cure-in-multiple-myeloma/

Jul 10th, 2021 - A Conversation With S. Vincent Rajkumar, MD The past 2 decades have seen so many advances in the treatment of multiple myeloma; in addition, median patient survival has grown from just 3 years in the late 1990s to between 8 and 10 years today,1 with some patients exceeding that prognosis by many years. Although still considered a stubbornly incurable cancer, higher rates of complete response ac...

Effect of Time to Surgery on Recurrence and Survival in Clinical Stage I NSCLC
https://ascopost.com/issues/july-10-2021/effect-of-time-to-surgery-on-recurrence-and-survival-in-clinical-stage-i-nsclc/

Jul 10th, 2021 - In a retrospective cohort study reported in JAMA Network Open, Heiden et al found that increased time from preoperative diagnostic computed tomography imaging and surgical treatment was associated with an increased risk of disease recurrence and poorer overall survival in patients with clinical stage I non–small cell lung cancer (NSCLC). As stated by the investigators, “The association between ...

Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
https://ascopost.com/issues/july-10-2021/enfortumab-vedotin-represents-a-community-of-work-in-antibody-drug-conjugate-targeting-cancer/

Jul 10th, 2021 - Christopher Hoimes, MD The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of Ghose et al,2 who published a paper on immunochemotherapy for cancer with a ...

Expert Point of View: Jacqueline C. Barrientos, MD
https://ascopost.com/issues/july-10-2021/epov-jacqueline-barrientos-1/

Jul 10th, 2021 - The invited discussant of the phase I trial of lisaftoclax (APG-2575), Jacqueline C. Barrientos, MD, of Hofstra/Northwell, Great Neck, New York, commented on the positive findings: “The 15 patients with chronic lymphocytic leukemia [CLL] had an objective response rate of 80% and a median time to response of two cycles, with a favorable safety profile. Only two discontinuations were related to t...

EV-301 Trial: Enfortumab Vedotin-ejfv Improves Overall Survival vs Chemotherapy in Previously Treated Advanced Urothelial Carcinoma
https://ascopost.com/issues/july-10-2021/enfortumab-vedotin-ejfv-improves-overall-survival-vs-chemotherapy-in-previously-treated-advanced-urothelial-carcinoma/

Jul 10th, 2021 - Thomas Powles, MD As reported in The New England Journal of Medicine by Thomas Powles, MD, of Barts Cancer Centre, Queen Mary University of London, and colleagues, a prespecified interim analysis of the phase III EV-301 trial has shown improved overall survival with the antibody-drug conjugate enfortumab vedotin-ejfv vs investigator’s choice of chemotherapy in patients with previously treated a...

Expert Point of View: Edward B. Garon, MD, MS
https://ascopost.com/issues/july-10-2021/epov-edward-garon/

Jul 10th, 2021 - Invited discussant of the BOOSTER trial,1 Edward B. Garon, MD, MS, Professor of Medicine and Director of the Thoracic Oncology Program, David Geffen School of Medicine at the University of California Los Angeles, said the study’s research question is appropriate, since osimertinib was established as the standard of care for patients with EGFR T790M mutations and disease progression on prior EGF...

Expert Point of View: Jacqueline C. Barrientos, MD, MS
https://ascopost.com/issues/july-10-2021/epov-jacqueline-barrientos/

Jul 10th, 2021 - Invited discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell in Great Neck, New York, noted that, although both ibrutinib and venetoclax have shown superior results to chemotherapy, each drug is associated with toxicity. “Ibrutinib is associated with cardiovascular toxicity and bleeding effects. Venetoclax can cause ne...

Expert Point of View: Jason J. Luke, MD
https://ascopost.com/issues/july-10-2021/epov-jason-luke/

Jul 10th, 2021 - Invited discussant of the C-144-01 study,1 Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, Pittsburgh, noted that lifileucel is “clearly an active regimen in the post–PD-1/CTLA-4 setting and one that differentiates mechanistically from other systemic approaches.” As Dr. Luke pointed out, for...